Investing.com - Financial Markets Worldwide

Shandong Boyuan Pharmaceutical & Chemical Co Ltd (301617)

Shenzhen
Currency in CNY
38.98
-0.17(-0.43%)
Closed·
301617 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
301617 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
38.6639.48
52 wk Range
34.87107.66
Key Statistics
Edit
Bid/Ask
38.98 / 38.98
Prev. Close
39.15
Open
39.1
Day's Range
38.66-39.48
52 wk Range
34.87-107.66
Volume
1.34M
Average Volume (3m)
2.62M
1-Year Change
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
301617 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 4
Liquid assets exceed short term obligations
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Shandong Boyuan Pharmaceutical & Chemical Co Ltd Company Profile

Shandong Boyuan Pharmaceutical & Chemical Co., Ltd. engages in the research and development, production, and sales of fine chemicals. The company offers iodine derivatives, such as potassium iodide, sodium iodide, potassium iodide, hydriodic acid, copper iodide, and iodotrimethylsilane; and fine chemicals, including hexamethyldisilazane, hexamethyldisilane, hexamethyldisiloxane, and tris[2-(2-methoxyethoxy)ethyl]amine. It also offers chemiluminescent products comprising 3,5-Dichlorosalicylic acid; 3,5,6-Trichlorosalicylic acid; bis(2,4,5-trichloro-6-carbopentoxyphenyl) oxalate; and Bis(2,4,5-trichloro-6-i-pentoxycarbonylphenyl) oxalate. In addition, the company provides precious metal catalysts, such as rhodium(ii) octanoate dimer, rhodium(iii) iodide, wilkinson’s catalyst, palladium acetate, rhodium(iii) chloride hydrate, palladium chloride, chloroplatinic acid hexahydrate, potassium platinochloride, potassium hexachloroplatinate, ruthenium(iii) chloride hydrate, rhodium (triphenylphosphine)carbonylacetylacetonate, tetrakis(triphenylphosphine)palladium, palladium on carbon, and ruthenium on carbon. Its products are used in pharmaceutical, chemical, optoelectronic materials, feed, food, and other fields. The company was founded in 2008 and is based in Shouguang, China.

Industry
-
Sector
-
Employees
667
Market
China

Compare 301617 to Peers and Sector

Metrics to compare
301617
Peers
Sector
Relationship
P/E Ratio
24.7x50.5x2.5x
PEG Ratio
-0.260.00
Price/Book
3.1x2.7x1.6x
Price / LTM Sales
3.9x3.5x1.3x
Upside (Analyst Target)
-−0.4%19.4%
Fair Value Upside
Unlock−4.2%2.2%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.94%
Dividend Yield
1.36%
Industry Median -
Annualised payout
0.53
Paid unevenly
5-Years Growth
-
Growth Streak
Unlock

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
0.37 / --
Revenue / Forecast
320.24M / --
EPS Revisions
a
a
Unlock
Last 90 days

301617 Income Statement

FAQ

What Stock Exchange Does Shandong Boyuan Pharmaceutical Trade On?

Shandong Boyuan Pharmaceutical is listed and trades on the Shenzhen Stock Exchange stock exchange.

What Is the Stock Symbol for Shandong Boyuan Pharmaceutical?

The stock symbol for Shandong Boyuan Pharmaceutical is "301617."

What Is the Shandong Boyuan Pharmaceutical Market Cap?

As of today, Shandong Boyuan Pharmaceutical market cap is 5.21B.

What Is Shandong Boyuan Pharmaceutical's Earnings Per Share (TTM)?

The Shandong Boyuan Pharmaceutical EPS (TTM) is 1.94.

From a Technical Analysis Perspective, Is 301617 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Shandong Boyuan Pharmaceutical Stock Split?

Shandong Boyuan Pharmaceutical has split 1 times.

How Many Employees Does Shandong Boyuan Pharmaceutical Have?

Shandong Boyuan Pharmaceutical has 667 employees.

What is the current trading status of Shandong Boyuan Pharmaceutical (301617)?

As of 30 Jul 2025, Shandong Boyuan Pharmaceutical (301617) is trading at a price of 38.98, with a previous close of 39.15. The stock has fluctuated within a day range of 38.66 to 39.48, while its 52-week range spans from 34.87 to 107.66.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.